Gunnarsson P O, Ellman M, Fabiansson E, Gunnarsson K, Jensen G, Müntzing J
Acta Pharmacol Toxicol (Copenh). 1981 Oct;49(4):290-7. doi: 10.1111/j.1600-0773.1981.tb00908.x.
LS 1727, a nitroso-chloroethyl carbamate of 19-nortestosterone, given intraperitoneally had a high cytostatic activity against some experimental tumours. In vitro studies showed that the tested tumours differed in their ability to hydrolyze LS 1727. The hydrolytic capacity was related to the sensitivity to treatment with LS 1727. Distribution studies with double-labelled LS 1727 demonstrated that the chloroethyl-part of the molecule was retained in dimethylbenz(a)anthracene-induced mammary tumours in the rat. Our findings suggest that the antitumour activity of LS 1727 is exerted by alkylating metabolites released at hydrolysis of the compound. LS 1727 had no oral antitumour activity probably due to pre-systemic hydrolysis. When given intravenously, hydrolysis of LS 1727 in lungs caused severe pulmonary toxicity already at low doses.
17α-甲基-17β-羟基雌甾-4-烯-3-酮亚硝基氯乙基氨基甲酸酯(LS 1727),一种19-去甲睾酮的亚硝基氯乙基氨基甲酸酯,腹腔注射时对某些实验性肿瘤具有高细胞抑制活性。体外研究表明,受试肿瘤在水解LS 1727的能力上存在差异。水解能力与对LS 1727治疗的敏感性相关。用双标记的LS 1727进行的分布研究表明,该分子的氯乙基部分保留在大鼠二甲基苯并(a)蒽诱导的乳腺肿瘤中。我们的研究结果表明,LS 1727的抗肿瘤活性是由该化合物水解时释放的烷基化代谢产物发挥的。LS 1727没有口服抗肿瘤活性,可能是由于其在进入体循环前就发生了水解。静脉注射时,LS 1727在肺部的水解即使在低剂量时也会导致严重的肺毒性。